Company news
Eli Lilly And Company (NYSE:LLY) news
Every Eli Lilly And Company press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
September 21, 2026
U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
September 18, 2026
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
September 15, 2026
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
September 11, 2026
Obesity Market Set for Explosive 27% CAGR Growth by 2036, Fueled by 7 Promising Emerging Therapies | DelveInsight
September 10, 2026
Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
September 8, 2026
Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
September 1, 2026
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
August 31, 2026
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
August 31, 2026
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
August 28, 2026
Eli Lilly and Company - Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
August 27, 2026
Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
August 26, 2026
Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases
August 19, 2026
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
August 12, 2026
Veeva Vault CRM Selected by Eli Lilly and Company
August 11, 2026
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
August 5, 2026
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
August 3, 2026
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
July 23, 2026
Lilly confirms date and conference call for second-quarter 2026 financial results announcement
July 22, 2026
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200
July 17, 2026
The Biotech Growth Trust PLC - Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc.
July 17, 2026
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
July 16, 2026
/C O R R E C T I O N -- Eli Lilly and Company/
July 9, 2026
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
July 9, 2026
Health Canada approves Mounjaro® (tirzepatide) for use in children 10 years and older living with type 2 diabetes
July 7, 2026
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios in Mainland China
July 1, 2026
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
June 30, 2026
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
June 26, 2026
NYSE Content Update: Abridge Partners with Eli Lilly, Nvidia to Improve Healthcare
June 24, 2026
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
June 24, 2026
ŌURA and LillyDirect to Expand Support for People Using GLP-1 Therapies with New Tools and Savings Options
June 23, 2026
Lilly declares third-quarter 2026 dividend
June 22, 2026
New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway
June 19, 2026
4E Therapeutics Acquired by Lilly to Advance Non-Opioid Approach to Chronic Pain
June 16, 2026
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
June 14, 2026
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
June 13, 2026
Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
June 10, 2026
ELI LILLY CANADA WELCOMES QUÉBEC PUBLIC REIMBURSEMENT OF VERZENIO® (ABEMACICLIB) FOR MBC FOLLOWING SUCCESSFUL PCPA NEGOTIATION
June 10, 2026
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
June 9, 2026
Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
June 8, 2026
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
June 7, 2026
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
June 6, 2026
Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases
June 3, 2026
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
June 2, 2026
Camurus announces expansion of Lilly collaboration
June 1, 2026
Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas
June 1, 2026
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
May 31, 2026
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
May 28, 2026
AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine
May 28, 2026
Foundayo and Zepbound now covered for millions of Americans
May 28, 2026